Literature DB >> 11516097

Prognostic evaluation of the microvascular network in myelodysplastic syndromes.

P Korkolopoulou1, E Apostolidou, P M Pavlopoulos, N Kavantzas, N Vyniou, I Thymara, E Terpos, E Patsouris, X Yataganas, P Davaris.   

Abstract

Considering the recently stated suggestion of neovascularization being implicated in myelodysplastic syndromes (MDS) pathogenesis, we evaluated multiple morphometric microvascular characteristics in MDS, in relation to clinicopathologic factors and prognosis. Trephines from 50 newly diagnosed MDS patients were immunostained for factor VIII and compared to those from 20 controls, 10 chronic myelomonocytic leukemia (CMML) and 12 acute myeloid leukemia (AML) patients. Quantitation of microvessel density (MVD), area, total vascular area (TVA), major and minor axis length, perimeter, compactness, shape factor, Feret diameter, and the number of branching vessels was performed by image analysis. Overall, the MDS group had significantly higher MVD, TVA, minor axis and shape factor values and significantly lower compactness than the control group. AML was characterized by increased vascularity compared to MDS and CMML, as well as by the presence of flattened microvessels (lower values of shape factor). Hypercellular MDS showed higher MVD. RA/RARS displayed larger caliber vessels than RAEB, which explains the favorable prognostic effect of increased size-related parameters on progression and/or survival. Moreover, decreased compactness and MVD were independent predictors of longer progression-free survival. It is concluded that angiogenesis is involved in the conversion of normal marrow to MDS and ultimately to AML and that disease progression within MDS is accompanied by qualitative alterations of the microvascular network. Furthermore, size-related parameters affect survival, while shape-related parameters and MVD are more influential with regard to progression-free survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516097     DOI: 10.1038/sj.leu.2402220

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  22 in total

1.  Angiogenesis and survival in patients with myelodysplastic syndrome.

Authors:  Aleksandar Savic; Vesna Cemerikic-Martinovic; Sinisa Dovat; Nebojsa Rajic; Ivana Urosevic; Borivoj Sekulic; Vanja Kvrgic; Stevan Popovic
Journal:  Pathol Oncol Res       Date:  2012-01-24       Impact factor: 3.201

2.  Leukemia regression by vascular disruption and antiangiogenic therapy.

Authors:  Gerard J Madlambayan; Amy M Meacham; Koji Hosaka; Saad Mir; Marda Jorgensen; Edward W Scott; Dietmar W Siemann; Christopher R Cogle
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

Review 3.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

Review 4.  Advances in understanding the leukaemia microenvironment.

Authors:  Yoko Tabe; Marina Konopleva
Journal:  Br J Haematol       Date:  2014-01-09       Impact factor: 6.998

5.  Angiogenic patterns and their quantitation in high grade astrocytic tumors.

Authors:  Suash Sharma; Mehar C Sharma; Deepak Kumar Gupta; Chitra Sarkar
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

6.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

Review 7.  Endothelial progenitor cells in hematologic malignancies.

Authors:  Ugo Testa; Ernestina Saulle; Germana Castelli; Elvira Pelosi
Journal:  Stem Cell Investig       Date:  2016-07-01

Review 8.  The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.

Authors:  Allison J Li; Laura M Calvi
Journal:  Exp Hematol       Date:  2017-08-18       Impact factor: 3.084

9.  Does CD34 Staining Reflect the Angiogenic Process in the Bone Marrow? An Analysis of a Series of Chronic Myeloid Leukemia Patients.

Authors:  Krishnan Kulumani Mahadevan; Debdatta Basu; Swarup Kumar
Journal:  J Clin Diagn Res       Date:  2014-05-15

10.  Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.

Authors:  Gautam Borthakur; Yesid Alvarado; Farhad Ravandi-Kashani; Jorge Cortes; Zeev Estrov; Stefan Faderl; Percy Ivy; Carlos Bueso-Ramos; B Nebiyou Bekele; Francis Giles
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.